384 related articles for article (PubMed ID: 34105767)
1. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Reich K; Gordon KB; Strober BE; Armstrong AW; Miller M; Shen YK; You Y; Han C; Yang YW; Foley P; Griffiths CEM
Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
[TBL] [Abstract][Full Text] [Related]
3. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
[TBL] [Abstract][Full Text] [Related]
6. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
10. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
Griffiths CEM; Papp KA; Song M; Miller M; You Y; Shen YK; Han C; Blauvelt A
J Dermatolog Treat; 2022 Mar; 33(2):848-856. PubMed ID: 32660282
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
[TBL] [Abstract][Full Text] [Related]
12. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
Puig L; Wu JJ; Gooderham MJ; You Y; Shen YK; Randazzo B; Kerdel F
J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
[TBL] [Abstract][Full Text] [Related]
13. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Reich K; Papp KA; Armstrong AW; Wasfi Y; Li S; Shen YK; Randazzo B; Song M; Kimball AB
Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
[TBL] [Abstract][Full Text] [Related]
14. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
16. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
Blauvelt A; Tsai TF; Langley RG; Miller M; Shen YK; You Y; Yang YW; Papp KA; Puig L
J Am Acad Dermatol; 2022 Apr; 86(4):827-834. PubMed ID: 34798201
[TBL] [Abstract][Full Text] [Related]
17. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
Puig L; Tsai TF; Bhutani T; Uy J; Ramachandran P; Song M; You Y; Gooderham M; Lebwohl M
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
Reich K; Foley P; Han C; McElligott S; Muser E; Li N; Armstrong AW
J Dermatolog Treat; 2020 Sep; 31(6):617-623. PubMed ID: 31305186
[No Abstract] [Full Text] [Related]
19. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
Jo SJ; Huang YH; Tsai TF; Kim BS; Reich K; Saadoun C; Chang CL; Yang YW; Youn SW
J Dermatol; 2023 Sep; 50(9):1180-1189. PubMed ID: 37341137
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Gordon KB; Blauvelt A; Foley P; Song M; Wasfi Y; Randazzo B; Shen YK; You Y; Griffiths CEM
Br J Dermatol; 2018 Jan; 178(1):132-139. PubMed ID: 28940259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]